Oruka Therapeutics, Inc. ORKA
Set alert
As of Nov 2, 11:41 AM ET
- YTD
- +215.18%
- 1 year
- +239.12%
- Open
- 98.85
- Prev close
- 96.87
- Mkt cap
- 6.33B
- Vol
- 178.75K
- Avg vol
- 892.48K
- EPS
- -2.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.74
- High
- 99.83
- Forward P/E
- -33.85
- Beta
- -0.11
- Short ratio
- 5.86
- Inst. own
- 116.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 88.63
- 200-d avg
- 68.91
- 1y target
- 156.17
5D chart
Events in this range
- Oct 27, 2026Rating: Wedbush · Outperform → Outperform
- Oct 27, 2026Rating: Guggenheim · Buy → Buy
Signals (114)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:10 AM | 1 hour ago |
| MACD: Sell Signal | Nov 2, 10:05 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 10:00 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:50 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:40 AM | 2 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 2 hours ago |
| RSI: Overbought | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 6 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 6 days ago |
| RSI: Overbought | Oct 27, 11:25 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 6 days ago |
News
-
6 days ago benzinga.com
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
-
6 days ago benzinga.com
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
-
6 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
6 days ago marketbeat.com
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its…
6 days ago seekingalpha.com
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
6 days ago benzinga.com
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
6 days ago benzinga.com
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Oruka Therapeutics reported positive Week 16 Phase 2b data for ORKA-001, showing 61% complete skin clearance in plaque psoriasis patients.
1 week ago benzinga.com
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday
U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
-
1 week ago benzinga.com
Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-AContinued favorable safety and tolerability profile consistent with the IL-23p19 classORKA-001 on…
1 week ago globenewswire.com
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on…
1 week ago globenewswire.com
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new…
2 weeks ago defenseworld.net
Oruka Therapeutics (NASDAQ:ORKA) Stock Keeps “Buy” Rating at BTIG Research
Oruka Therapeutics (NASDAQ: ORKA - Get Free Report)'s stock had its "buy" rating restated by analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a…
-
2 weeks ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
2 weeks ago seekingalpha.com
Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End
Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28…
1 month ago zacks.com
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.
1 month ago benzinga.com
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics reports positive week 28 results from its Phase 2a trial for plaque psoriasis treatment ORKA-001.
-
1 month ago benzinga.com
Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026
Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis."These Week 28 results, with responses…
1 month ago globenewswire.com
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001…
1 month ago globenewswire.com
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
2 months ago zacks.com
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
2 months ago defenseworld.net
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA
BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
2 months ago globenewswire.com
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new…
2 months ago zacks.com
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
-
2 months ago benzinga.com
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
-
2 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
-
2 months ago benzinga.com
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of…
2 months ago globenewswire.com
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
-
3 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
4 months ago benzinga.com
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares
Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.
-
4 months ago benzinga.com
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.
4 months ago fool.com
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
4 months ago fool.com
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
4 months ago benzinga.com
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC,…
4 months ago zacks.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 months ago zacks.com
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
-
5 months ago benzinga.com
Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment
On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment to IL-23 License Agreement (the "Amendment"), amending the IL-23 License Agreement dated as of December 17,…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
-
5 months ago benzinga.com
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
-
5 months ago benzinga.com
Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of…
-
6 months ago benzinga.com
Oruka Therapeutics Files Prospectus For Offering 9.66M Common Shares
https://www.sec.gov/Archives/edgar/data/907654/000121390026049372/ea0288174-424b5_oruka.htm
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $120.
6 months ago benzinga.com
CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
-
6 months ago benzinga.com
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $100.